

## Type 2 Diabetes in adults (medicines update) Committee meeting 10 Day 1

**Date:** 18/07/2024

**Location:** Hybrid, NICE Manchester Office

**Minutes:** Final

| <b>Committee members present:</b> |                                      |
|-----------------------------------|--------------------------------------|
| Waqar Shah (Chair)                | Present for notes 1 – 6              |
| Chirag Bakhai                     | Present for notes 1 – 6              |
| Catherine Bewsey                  | Present for notes 1 – 6              |
| Mimi Chen                         | Present for notes 1 – 6              |
| Sithembile Thokozile Chinaire     | Present for notes 1 – 6              |
| Hussain Contractor                | Present for notes 1 – 6              |
| Dan Cuthbertson (Topic Adviser)   | Present for notes 1 – 6              |
| Anne Dornhorst                    | Present for notes 1 – 6              |
| Hugh Gallagher                    | Present for notes 1 – 6              |
| Natasha Jacques                   | Present for notes 1 – 6              |
| Sallianne Kavanagh                | Present for notes 1 – 6              |
| Sharon McCarthy                   | Present for notes 1 – 6              |
| Soon Song                         | Present for notes 1 – 6              |
| Annette Swinkels                  | Present for notes 1 – 6              |
| Dominic Taylor                    | Present until partway through item 4 |
| John Turner                       | Present for notes 1 – 6              |

| <b>In attendance:</b> |                          |                         |
|-----------------------|--------------------------|-------------------------|
| Astrid Aregui         | Senior Medical Editor    | Present for notes 1 – 6 |
| Jackie Durkin         | Administrator            | Present for notes 1 – 3 |
| Sarah Dwyer           | Technical Analyst        | Present for notes 1 – 6 |
| James Hawkins         | Health Economics Adviser | Present for notes 1 – 6 |
| Lina Manounah         | Technical Analyst        | Present for notes 1 – 6 |

|                     |                                       |                         |
|---------------------|---------------------------------------|-------------------------|
| Sarah Matthews      | Technical Analyst                     | Present for notes 1 – 6 |
| Gregory Moran       | Medicines Analyst                     | Present for notes 1 – 6 |
| Caroline Mulvihill  | Topic Lead                            | Present for notes 1 – 6 |
| Sade Naku           | Health Economist                      | Present for notes 1 – 6 |
| Adam O’Keefe        | Project Manager                       | Present for notes 1 – 6 |
| Eric Power          | Centre for Guidelines Deputy Director | Present until item 4    |
| Nancy Pursey        | Assistant Technical Analyst           | Present for notes 1 – 6 |
| Muksitur Rahman     | Health Economist                      | Present for notes 1 – 6 |
| Emily Terrazas-Cruz | Senior Technical Analyst              | Present for notes 1 – 6 |
| Philip Williams     | Finance Analyst                       | Present for notes 1 – 6 |

**NICE observer:**

|  |                         |
|--|-------------------------|
| Patrick Langford, Technical Analyst, Centre for Guidelines | Present for notes 1 – 6 |
|--|-------------------------|

**Apologies:**

|              |                                |
|--------------|--------------------------------|
| Neel Basudev | Committee member               |
| Gosia Wamil  | Committee member               |
| Sarah Glover | Information Specialist, NICE   |
| George Wood  | Senior Technical Analyst, NICE |

**1. Welcome, introductions and apologies**

The Chair welcomed the Committee members and attendees to Day one of the tenth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked committee members to verbally declare any new interests, these are noted below:

| Name           | Job title, organisation | Declarations of Interest, date declared              | Type of interest  | Decision taken                  |
|----------------|-------------------------|--|-------------------|---------------------------------|
| Hugh Gallagher | Committee member, Renal | Appointed Clinical Advisor for an upcoming review of | Direct, financial | Declare and participate<br>Open |

|   |           |   |  |   |
|---|-----------|---|--|---|
|   | Physician | NICE TA775<br>(Dapagliflozin for<br>treating chronic<br>kidney disease) |  | declaration<br>considered to be<br>sufficient<br>mitigation |
| The Chair and a senior member of the Developer's team noted that otherwise, the interests declared did not prevent the attendees from fully participating in the meeting.   |           |   |  |   |
| <b>3. Minutes of previous meeting</b>   |           |   |  |   |
| The minutes of the previous meeting were accepted as a true and accurate record.  |           |   |  |   |
| <b>Update on incorporation and integration of NICE TAs</b>  |           |   |  |   |
| The Chair introduced NICE Centre for Guidelines Deputy Director Eric Power who provided the committee with an update on the ongoing work to incorporate and integrate NICE Technology Appraisals into its clinical guidelines and the implications for this guideline update.   |           |   |  |   |
| <b>4. Health economics: Presentation and discussion of Health economic model and related clinical outcomes</b>  |           |   |  |   |
| The Chair introduced NICE Health Economics Adviser James Hawkins, who contextualised and updated the committee on progress with the health economic model being developed to support this guideline update. Health economists Sade Naku and Muksitur Rahman then held further discussion with the committee, including on subgroups modelled, modelling inputs and modelling results. |           |   |  |   |
| <b>5. Agree Minimally Important Differences (MIDs)</b>  |           |   |  |   |
| This item was deferred due to time constraints.   |           |   |  |   |
| <b>6. AOB</b>   |           |   |  |   |
| The Chair reminded the group that Day two of the meeting is scheduled to commence at 10:00 the following day, thanked participants and closed the meeting.  |           |   |  |   |

## Type 2 Diabetes in adults (medicines update) Committee meeting 10 Day 2

**Date:** 09/07/2024

**Location:** Virtual

**Minutes:** Final

| <b>Committee members present:</b> |                                      |
|-----------------------------------|--------------------------------------|
| Waqaar Shah (Chair)               | Present for notes 1 – 7              |
| Chirag Bakhai                     | Present for notes 1 – 7              |
| Catherine Bewsey                  | Present for notes 1 – 7              |
| Mimi Chen                         | Present for notes 1 – 7              |
| Sithembile Thokozile Chinaire     | Present for notes 1 – 7              |
| Dan Cuthbertson (Topic Adviser)   | Present from partway through item 5  |
| Anne Dornhorst                    | Present for notes 5 – 7              |
| Natasha Jacques                   | Present for notes 1 – 7              |
| Sallianne Kavanagh                | Present for notes 1 – 7              |
| Sharon McCarthy                   | Present for notes 1 – 7              |
| Soon Song                         | Present for notes 1 – 7              |
| Annette Swinkels                  | Present until partway through item 5 |
| John Turner                       | Present for notes 1 – 7              |

| <b>In attendance:</b> |                                   |                         |
|-----------------------|-----------------------------------|-------------------------|
| Astrid Aregui         | Senior Medical Editor             | Present for notes 1 – 7 |
| Jackie Durkin         | Administrator                     | Present for notes 1 – 2 |
| Sarah Dwyer           | Technical Analyst                 | Present for notes 1 – 7 |
| James Hawkins         | Health Economics Adviser          | Present for notes 1 – 7 |
| Lina Manounah         | Technical Analyst                 | Present for notes 1 – 7 |
| Sarah Matthews        | Technical Analyst                 | Present for notes 1 – 7 |
| Gregory Moran         | Medicines Analyst                 | Present for notes 1 – 7 |
| Caroline Mulvihill    | Technical Adviser, Guideline Lead | Present for notes 1 – 7 |
| Sade Naku             | Health Economist                  | Present for notes 1 – 7 |
| Adam O'Keefe          | Project Manager                   | Present for notes 1 – 7 |

|                     |                             |                         |
|---------------------|-----------------------------|-------------------------|
| Nancy Pursey        | Assistant Technical Analyst | Present for notes 1 – 7 |
| Muksitur Rahman     | Health Economist            | Present for notes 1 – 7 |
| Emily Terrazas-Cruz | Senior Technical Analyst    | Present for notes 1 – 7 |
| Philip Williams     | Finance Analyst             | Present for notes 1 – 7 |

**Expert witness present:**

|   |                         |
|---|-------------------------|
| Dr Michael Ni'Man, Chair of TransGapProject | Present for notes 1 – 3 |
|---|-------------------------|

**NICE observers:**

|  |                         |
|--|-------------------------|
| Lee-Yee Chong, Technical Analyst, Centre for Guidelines    | Present for notes 1 – 7 |
| Patrick Langford, Technical Analyst, Centre for Guidelines | Present for notes 1 – 7 |

**Apologies:**

|                    |                                |
|--------------------|--------------------------------|
| Neel Basudev       | Committee member               |
| Hussain Contractor | Committee member               |
| Hugh Gallagher     | Committee member               |
| Dominic Taylor     | Committee member               |
| Gosia Wamil        | Committee member               |
| Sarah Glover       | Information Specialist, NICE   |
| George Wood        | Senior Technical Analyst, NICE |

**1. Welcome, introductions and apologies**

The Chair welcomed the Committee members and attendees to Day two of the tenth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.

The Chair asked committee members to verbally declare any new interests, no new interests were declared.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Expert testimony: TransGap**

The Chair introduced Caroline Mulvihill, Topic Lead, who briefly outlined the role and purpose of expert witnesses in guideline development, for the committee's benefit. The Chair then introduced Dr Michael Ni'Man who talked to the committee about the gap in diabetes care for trans people. The committee discussed the presentation and asked questions. The Chair thanked Dr Ni'Man for his contribution to the meeting.

### **4. Demonstration of interactive tool**

The Chair introduced Sarah Matthews, Technical Analyst, who demonstrated to the committee an interactive tool built by members of the NICE team to aid recommendation drafting.

### **5. Health economics model results**

The Chair re-introduced Health Economists Sade Naku and Muksitur Rahman who further discussed the health economic modelling being developed in support of the guideline update with the committee.

### **6. Recommendation drafting**

The Chair introduced Astrid Aregui, Senior Medical Editor, who provided the committee with editorial guidance on drafting recommendations.

The committee agreed to wait until the following meeting to draft further recommendations.

### **7. AOB**

The Chair thanked participants and closed the meeting.

**Date of next meeting:** Guideline Committee Meeting 11: Thursday 5<sup>th</sup> and Friday 6<sup>th</sup> September 2024

**Location of next meeting:** Hybrid, NICE London office